Innate Pharma (XPAR:IPH) Interest Expense : €-0.64 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Innate Pharma's interest expense for the six months ended in Dec. 2023 was € 0.33 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.64 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Innate Pharma's Operating Income for the six months ended in Dec. 2023 was € -12.27 Mil. Innate Pharma's Interest Expense for the six months ended in Dec. 2023 was € 0.33 Mil. Innate Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innate Pharma Interest Expense Historical Data

The historical data trend for Innate Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Interest Expense Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.20

-0.34

-0.31

-0.29

-0.64

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.15	-6.17	5.88	-0.97	0.33

Innate Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.64 Mil.

Innate Pharma (XPAR:IPH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innate Pharma's Interest Expense for the six months ended in Dec. 2023 was €0.33 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-12.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was €30.96 Mil.

Innate Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines